OVERVIEW

Amid the COVID-19 Pandemic, the U.S. insomnia treatment market is expected to cross USD 7.12 billion by 2026, growing at a CAGR of 4.02% from 2021-2026. This rise can be due to the advent of new medications to treat insomnia and government funding to reduce the increasing cost of insomnia. Nonetheless, due to the decline in the sales of branded drugs and the may acceptance of generics due to their low cost and equivalent effectiveness as opposed to branded products, market growth could be hampered.

TABLE OF CONTENT

• 2 RESEARCH METHODOLOGY
  • 2.1 Research Data
    • 2.1.1 Secondary Data
      • 2.1.1.1 Key Data From Secondary Sources
    • 2.1.2 Primary Data
      • 2.1.2.1 Key Data From Primary Sources
      • 2.1.2.2 Key Industry Insights
      • 2.1.2.3 Breakdown of Primaries
  • 2.2 Market Size Estimation
    • 2.2.1 Bottom-Up Approach
    • 2.2.2 Top-Down Approach
  • 2.3 Market Breakdown and Data Triangulation
  • 2.4 Research Assumptions

• 3 U.S. Insomnia Market ? Executive Summary
  • 3.1 Market Revenue, Market Size and Key Trends by Company
  • 3.2 Key Trends by type of Application
  • 3.3 Key Trends segmented by Geography

• 4 U.S. Insomnia Market ? Industry Market Entry Scenario
  • 4.1 Regulatory Framework Overview
  • 4.2 New Business and Ease of Doing business index
  • 4.3 Case studies of successful ventures
  • 4.4 Customer Analysis ? Top 10 companies

• 5 U.S. Insomnia Market - Market Forces
  • 5.1 Introduction
  • 5.2 Market Dynamics
    • 5.2.1 Drivers
    • 5.2.2 Opportunities
    • 5.2.3 Challenges
  • 5.3 Porters Analysis of Market
    • 5.3.1 Bargaining power of suppliers
    • 5.3.2 Bargaining powers of customers
    • 5.3.3 Threat of new entrants
    • 5.3.4 Rivalry among existing players
    • 5.3.5 Threat of substitutes

• 6 U.S. Insomnia Market - Strategic Analysis
  • 6.1 Value Chain analysis
  • 6.2 Supplier and distributor analysis (Market share and product dealing strategies)

• 7 U.S. Insomnia Market ? By Treatment (Market Size ? & million/billion)
  • 7.1 Pharmacological Treatments
  • 7.2 Non-pharmacological Treatments

• 8 U.S. Insomnia Market - By Pharmacological Treatment
  • 8.1 Prescription Sleep Aids
  • 8.2 Over-the-Counter Sleep Aids

• 9 U.S. Insomnia Market - By Non-pharmacological Treatment
  • 9.1 Cognitive Behavioral Therapy for Insomnia (CBTI)
  • 9.2 Hypnotherapy
  • 9.3 Other

• 10 U.S. Insomnia Market ? Entropy
  • 10.1 New product launches
  • 10.2 M&A's, collaborations, JVs and partnerships

• 11 U.S. Insomnia Market Company Profile (Key Players)
  • 11.1 Market Share, Company Revenue, Products, M&A, Developments
  • 11.2 Merck & Co., Inc.
  • 11.3 Eisai Co., Ltd.
  • 11.4 Meda Consumer Healthcare, Inc
  • 11.5 Takeda Pharmaceuticals Company Ltd.
  • 11.6 Purdue Pharmaceuticals L.P.
  • 11.7 Sanofi
  • 11.8 Vanda Pharmaceuticals
  • 11.9 Pernix Therapeutics
  • 11.10 Pfizer Inc.
  • 11.11 Company 10
  • 11.12 Company 11 & more

• 12 U.S. Insomnia Market - Appendix
  • 12.1 Sources
  • 12.2 Abbreviations